Previous 10 | Next 10 |
European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2 PR Newswire BioMarin Submits Supplemental New Drug Application to U.S. Food and Drug Administration t...
Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...
BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A PR Newswire FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application ...
Summary BioMarin provided quarterly reports. The EBITDA margin is improving. The next step is to increase net profit. Voxzogo's sales are better than expected. The expanding into new indications is in focus. The AdCom for ValRox scared off investors. As a result of the rep...
BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program PR Newswire FDA Pre-Licensure Inspection of Gene Therapy Manufacturing Facility Scheduled ...
BioMarin to Participate in Two Upcoming Investor Conferences PR Newswire Credit Suisse 31st Annual Healthcare Conference 2022: November 8th , 8:35amPT / 11:35amET , in Rancho Palos Verdes, CA 13th Annual Jefferies Global Healthcare Conference ...
BioMarin Pharmaceuticals (NASDAQ: BMRN) , a biopharmaceutical company that specializes in finding therapies for rare genetic diseases, saw its shares drop 6.9% on Thursday after falling as much as 9.8% earlier in the day. The stock closed on Wednesday at $92.10, then opened on Thurs...
Biomarin Pharmaceutical, Inc. (BMRN) Q3 2022 Earnings Conference Call October 26, 2022, 16:30 ET Company Participants Traci McCarty - VP, IR J.J. Bienaime - Chairman & CEO Jeffrey Ajer - EVP & Chief Commercial Officer Henry Fuchs - President, Worldwid...
Although BioMarin Pharmaceutical ( NASDAQ: BMRN ) saw its net loss narrow 82% in Q3 to $6.7M from a loss of $26.5M in the year-ago period, that was not good enough to beat on the bottom line . Revenue in the quarter of ~$505M, a ~24% year-over-year increase, was also a...
BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q3 GAAP EPS of -$0.04 misses by $0.03 . Revenue of $505.3M (+23.6% Y/Y) misses by $10.56M . For FY2022, the company expects $2.06B to $2.16B vs. consensus of $2.12B and Non-GAAP net income in the range of ...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...